Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Tanja D de Gruijl"'
Autor:
Kamran Nazmi, Tanja D. de Gruijl, Gert Storm, Medha D. Joshi, Erik Hooijberg, Jan G. M. Bolscher, Yvette van Kooyk, Martino Ambrosini, Wendy W. J. Unger, Sven C. M. Bruijns, Hakan Kalay, Astrid J. van Beelen, Marleen I. Verstege, Louis van Bloois, Cynthia M. Fehres
Publikováno v:
Journal of Controlled Release, 160(1), 88-95. Elsevier
Unger, W W J, van Beelen, A J, Bruijns, S C M, Joshi, M, Fehres, C M, van Bloois, L, Verstege, M I, Ambrosini, M, Kalay, H, Nazmi, K, Bolscher, J G, Hooijberg, E, de Gruijl, T D, Storm, G & van Kooyk, Y 2012, ' Glycan-modified liposomes boost CD4(+) and CD8(+) T-cell responses by targeting DC-SIGN on dendritic cells ', Journal of Controlled Release, vol. 160, no. 1, pp. 88-95 . https://doi.org/10.1016/j.jconrel.2012.02.007
Unger, W W J, van Beelen, A J, Bruijns, S C, Joshi, M, Fehres, C M, van Bloois, L, Verstege, M I, Ambrosini, M, Kalay, H, Nazmi, K, Bolscher, J G, Hooiberg, E, de Gruijl, T D, Storm, G & van Kooyk, Y 2012, ' Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells ', Journal of Controlled Release, vol. 160, no. 1, pp. 88-95 . https://doi.org/10.1016/j.jconrel.2012.02.007
Unger, W W J, van Beelen, A J, Bruijns, S C M, Joshi, M, Fehres, C M, van Bloois, L, Verstege, M I, Ambrosini, M, Kalay, H, Nazmi, K, Bolscher, J G, Hooijberg, E, de Gruijl, T D, Storm, G & van Kooyk, Y 2012, ' Glycan-modified liposomes boost CD4(+) and CD8(+) T-cell responses by targeting DC-SIGN on dendritic cells ', Journal of Controlled Release, vol. 160, no. 1, pp. 88-95 . https://doi.org/10.1016/j.jconrel.2012.02.007
Unger, W W J, van Beelen, A J, Bruijns, S C, Joshi, M, Fehres, C M, van Bloois, L, Verstege, M I, Ambrosini, M, Kalay, H, Nazmi, K, Bolscher, J G, Hooiberg, E, de Gruijl, T D, Storm, G & van Kooyk, Y 2012, ' Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells ', Journal of Controlled Release, vol. 160, no. 1, pp. 88-95 . https://doi.org/10.1016/j.jconrel.2012.02.007
Cancer immunotherapy requires potent tumor-specific CD8(+) and CD4(+) T-cell responses, initiated by dendritic cells (DCs). Tumor antigens can be specifically targeted to DCs in vivo by exploiting their expression of C-type lectin receptors (CLR), wh